MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES

• US 20090048267A1
• Filed: 05/12/2008
• Published: 02/19/2009
• Est. Priority Date: 12/24/2004
• Status: Abandoned Application

• Current Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: PARK, John Edward, Chaudhary, Nveed, Dahmann, Georg, Grauert, Matthias, Heckel, Armin, Roth, Gerald Juergen, Lehmann-Lintz, Thorsten, Kley, Joerg, Brandl, Trixi
• Application Number:
  US12/118,992
• Publication Number:
  US 20090048267A1
• Time in Patent Office: Days
• US Class Current: 514/254.90
• CPC Class Codes: A61K 31/404 Indoles, e.g. pindolol
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to the use of indolinones of general formula

substituted in the 6 position, wherein R₁, to R₅ and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.

Claims

1. A method for preventing or treating a fibrotic disease selected from the group consisting of fibrosis and remodeling of lung tissue in chronic obstructive pulmonary disease, fibrosis and remodeling of lung tissue in chronic bronchitis, fibrosis and remodeling of lung tissue in emphysema, lung fibrosis and pulmonary diseases with a fibrotic component, fibrosis and remodeling in asthma, fibrosis in rheumatoid arthritis, virally induced hepatic cirrhosis, radiation-induced fibrosis, post angioplasty restenosis, chronic glomerulonephritis, renal fibrosis in patients receiving cyclosporine and renal fibrosis due to high blood pressure, diseases of the skin with a fibrotic component, and excessive scarring comprising administering a therapeutically effective amount of an indolinone of formula

substituted in the 6 position, wherein

X denotes an oxygen or sulphur atom,

R₁, denotes a hydrogen atom or a prodrug group,

R₂ denotes a carboxy group, a straight-chain or branched C_1-6-alkoxycarbonyl group, a C_4-7-cycloalkoxycarbonyl or an aryloxycarbonyl group,

R₃ denotes a hydrogen atom, a C_1-6-alkyl, C_3-7-cycloalkyl, trifluoromethyl or heteroaryl group,

a phenyl or naphthyl group, or a phenyl or naphthyl group mono- or disubstituted by a fluorine, chlorine, bromine or iodine atom, by a trifluoromethyl, C_1-3-alkyl or C_1-3-alkoxy group, while in the event of disubstitution the substituents may be identical or different,

R₄ denotes a phenyl, pyrrolyl or furanyl group substituted by the group R₆, which may additionally be mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms, by C_1-5-alkyl, trifluoromethyl, hydroxy, C_1-3-alkoxy, carboxy, C_1-3-alkoxycarbonyl, amino, acetylamino, C_1-3-alkyl-sulphonylamino, aminocarbonyl, C_1-3-alkyl-aminocarbonyl, di-(C_{1 3}-alkyl)-aminocarbonyl, aminosulphonyl, C_1-3-alkyl-aminosulphonyl, di-(C_1-3-alkyl)-aminosulphonyl, nitro or cyano groups, while the substituents may be identical or different and wherein

R₆ denotes an aminocarbonyl, C_1-4-alkylamino-carbonyl, N—

(C_1-5-alkyl)-C_1-3-alkylaminocarbonyl, C_1-7-cycloalkyl-amino-carbonyl, N—

(C_1-5-alkyl)-C_3-7-cycloalkylaminocarbonyl, (phenyl-C_1-3-alkyl)amino-carbonyl, N—

(C_1-3-alkyl)-phenyl-C₁₃-al-kylamino-carbonyl group,

a C_1-3-alkylaminocarbonyl or N—

(C_1-3-alkyl)-C_1-3-alkylaminocarbonyl group wherein one or two alkyl moieties are substituted independently of one another by a nitro, cyano, carbamoyl, N—

(C_1-3-alkyl)-carbamoyl, di-N—

(C_1-3-alkyl)-carbamoyl, carboxy or C_1-3-alkoxycarbonyl group or are substituted in the 2- or 3-position by an amino, (C_1-3-alkyl)-amino, di-(C_1-3-alkyl)-amino, (C_1-4-alkoxycarbonyl)-amino, N—

(C_1-4-alkoxycarbonyl)-N—

(C_1-3-alkyl)-amino, piperazino, N—

(C_1-3-alkyl)-piperazino, a 4- to 7-membered cycloalkyleneimino group, a hydroxy or methoxy group, a 4- to 7-membered cycloalkyleneiminocarbonyl group wherein

the cycloalkylene moiety may be fused to a phenyl ring via two adjacent ring atoms or may form a bridge to a methylene or ethylene group via two non-adjacent ring atoms or

one or two hydrogen atoms may each be replaced by a C_1-3-alkyl group and/or

in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneiminocarbonyl group may be substituted by a carboxy, C_1-4-alkoxycarbonyl, aminocarbonyl, C_1-3-alkylaminocarbonyl, di-(C_{1 3}-alkyl)-aminocarbonyl, di-(C_1-2-alkyl)-amino-C_1-3-alkyl, di-(C_1-3-alkyl)-amino, phenyl-C_1-3-alkyl-amino or N—

(C_1-3-alkyl)-phenyl-C_1-3-alkylamino group or a hydroxy or methoxy group or

may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl or —

NH group or by a nitrogen atom which is substituted by a C_1-3-alkyl, phenyl, C_1-3-alkyl-carbonyl, C_1-4-alkoxy-carbonyl, di-(C_1-3-alkyl)-amino-C_1-3-alkyl, .-hydroxy-C_2-3-alkyl or benzoyl group,

while all the single-bonded or fused phenyl groups contained in the groups mentioned under R₆ may be mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms, by C_1-5-alkyl, trifluoromethyl, hydroxy, C_1-3-alkoxy, carboxy, C_1-3-alkoxycarbonyl, aminocarbonyl, C_1-4-alkylamino-carbonyl, di-(C_1-4-alkyl)-amino-carbonyl, aminosulphonyl, C_1-3-alkyl-aminosulphonyl, di-(C_1-3-alkyl)-aminosulphonyl, C_1-3-alkyl-sulphonylamino, nitro or cyano groups, while the substituents may be identical or different, or two adjacent hydrogen atoms of the phenyl groups may be replaced by a methylenedioxy group,

and

R₅ denotes a hydrogen atom or a C_1-3-alkyl group,

while by the term aryl group is meant a phenyl or naphthyl group optionally mono- or disubstituted by a fluorine, chlorine, bromine or iodine atom, by a cyano, trifluoromethyl, nitro, carboxy, aminocarbonyl, C_1-3-alkyl or C_1-3-alkoxy group and

by the term heteroaryl group is meant a monocyclic 5- or 6-membered heteroaryl group optionally substituted in the carbon skeleton by a C_1-3-alkyl group, wherein

the 6-membered heteroaryl group contains one, two or three nitrogen atoms and

the 5-membered heteroaryl group contains an imino group optionally substituted by a C_1-3-alkyl or phenyl-C_1-3-alkyl group, an oxygen or sulphur atom or

an imino group optionally substituted by a C_1-3-alkyl or phenyl-C_1-3-alkyl group or an oxygen or sulphur atom and additionally a nitrogen atom or

an imino group optionally substituted by a C_1-3-alkyl or phenyl-C_1-3-alkyl group and two nitrogen atoms,

and moreover a phenyl ring may be fused to the abovementioned monocyclic heterocyclic groups via two adjacent carbon atoms and the bond is via a nitrogen atom or via a carbon atom of the heterocyclic moiety of a fused phenyl ring,

the hydrogen atoms in the abovementioned alkyl and alkoxy groups or in the alkyl moieties contained in the above-defined groups of formula I may be wholly or partly replaced by fluorine atoms,

the saturated alkyl and alkoxy moieties containing more than 2 carbon atoms present in the groups defined above also include the branched isomers thereof such as for example the isopropyl, tert.butyl, isobutyl group, unless otherwise stated, and

wherein additionally the hydrogen atom of any carboxy group present or a hydrogen atom bound to a nitrogen atom, for example an amino, alkylamino or imino group or a saturated N-heterocycle such as the piperidinyl group, may be replaced in each case by a group which can be cleaved in vivo,

or a salt thereof.

2. The method as recited in claim 1 wherein the substituted indolinone of formula I is selected from the group consisting of:

(a) methyl 3-(Z)-[1-{4-[N-(2-dimethylamino-ethyl)-N-methyl-carbamoyl]-phenylamino}-1-phenyl-methylidene]-2-indolinone-6-carboxylate

(b) methyl 3-(Z)-[1-{4-[N-(3-dimethylamino-propyl)-N-methyl-carbamoyl]-phenylamino}-1-phenyl-methylidene]-2-indolinone-6-carboxylate

(c) methyl 3-(Z)-[1-{4-[(4-methyl-piperazin-1-yl)-carbonyl]-phenylamino}-1-phenyl-methylidene]-2-indolinone-6-carboxylate

(d) methyl 3-(Z)-[1-{4-[(4-hydroxy-piperidin-1-yl)-carbonyl]-phenylamino}-1-phenyl-methylidene]-2-indolinone-6-carboxylate

(e) methyl 3-(Z)-[1-{4-[(piperazin-1-yl)-carbonyl]-phenylamino}-1-phenyl-methylidene]-2-indolinone-6-carboxylate

(f) methyl 3-(Z)-[1-{4-[N-(2-methylamino-ethyl)-N-methyl-carbamoyl]-phenylamino}-1-phenyl-methylidene]-2-indolinone-6-carboxylate

(g) methyl 3-(Z)-[1-{4-[(4-dimethylamino-piperidin-1-yl)-carbonyl]-phenylamino}-1-phenyl-methylidene]-2-indolinone-6-carboxylate

(h) methyl 3-(Z)-[1-{4-[(4-ethyl-piperazin-1-yl)-carbonyl]-phenylamino}-1-phenyl-methylidene]-2-indolinone-6-carboxylate

(i) methyl 3-(Z)-[1-{4-[(4-(2-hydroxy-ethyl)-piperazin-1-yl)-carbonyl]-phenylamino}-1-phenyl-methylidene]-2-indolinone-6-carboxylate

(k) methyl 3-(Z)-{1-[4-(5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl-carbonyl)-phenylamino]-1-phenyl-methylidene}-2-indolinone-6-carboxylate

(l) (S)-3-(Z)-[1-{4-[(3,4-dimethyl-piperazin-1-yl)-carbonyl]-phenylamino}-1-phenyl-methylidene]-6-methoxycarbonyl-2-indolinone, and

(m) 3-(Z)-[1-{5-[(2-dimethylamino-ethyl)-N-methyl-carbamoyl]-furan-2-yl-amino}-1-phenyl-methylidene]-6-methoxycarbonyl-2-indolinone,

or a salt of any of the above recited indolines.

3. The method as recited in claim 1 wherein the disease is selected from the group consisting of the lung fibrosis and pulmonary diseases with a fibrotic component selected from idiopathic pulmonary fibrosis, giant cell interstitial pneumonia, sarcoidosis, cystic fibrosis, respiratory distress syndrome, drug-induced lung fibrosis, granulomatosis, silicosis, asbestosis, systemic scleroderma, the virally induced hepatic cirrhosis selected from hepatitis C induced hepatic cirrhosis, and the diseases of the skin with a fibrotic component selected from scleroderma, sarcoidosis and systemic lupus erythematosus.

4. The method as recited in claim 3 wherein the disease is idiopathic pulmonary fibrosis.

5. The method as recited in claim 1 further comprising administering an additional pharmacologically active substance selected from the group consisting of anticholinergic agents, beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK₁ antagonists, LTD4 antagonists, EGFR inhibitors and endothelin-antagonists in combination with the indoline of formula I.

6. A pharmaceutical composition comprising an indoline of formula I as recited in claim 1, or a salt thereof, an additional pharmacologically active substance selected from the group consisting of anticholinergic agents, beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP Kinase inhibitors, NK₁ antagonists, LTD4 antagonists, EGFR inhibitors and endothelin antagonists, and one or more pharmaceutically acceptable carriers or excipients.